Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STP938 in Advanced Solid Tumors and CTPS2 Null Ovarian Cancer
NCT06297525Phase 1Recruiting
- Sponsor
- StepPharma
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of dencatistat in solid tumor and ovarian cancer (2 arms), sponsored by StepPharma. Primary endpoint: Safety and Tolerability at 6 months. Started Aug 2024; status: recruiting.
02
Drugs
dencatistat
03
Conditions
solid tumorovarian cancer
Beyond the preview
Go deeper on NCT06297525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06297525.